Safety and efficacy of pembrolizumab as first-line therapy in non-small cell lung cancer patients with poor performance status: a pilot study.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Oct 2017 New trial record